课题基金 / 基金详情

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):由病原微生物、病毒或寄生虫引起的传染病是对人类健康的主要威胁,每年导致的死亡人数占世界总死亡人数的16.2%。迫切需要发现有效的治疗方法来对抗这些疾病并挽救生命。Pradimicin A是一种抗真菌和抗病毒的天然产物,产自芙蓉放线瘤P157-2。pradimicins的水溶性差和副作用阻碍了其抗感染药物的发展。为了利用pradimicin A显著的生物活性,寻找有前景的抗感染候选药物,本学术研究增强奖(AREA) R15申请是研究pradimicin A的生物合成途径,并利用酶和化学方法合成新的pradimicin类似物。本研究的三个中心假设是:1)完整的pradimicin A生物合成途径可以在异源宿主中重组和工程化;2)外源糖段和相应的糖基转移酶可被工程引入普拉地米星生物合成途径;3)新的pradimicin类似物(如含有不同氨基糖的类似物)具有抗真菌和抗病毒活性。研究人员将测试这些中心假设,并通过追求四个具体目标来实现该项目的总体目标:1)研究普拉地米星A生物合成的后期剪裁步骤;2)设计新型pradimicin类似物的生物合成;3)化学合成新型pradimicin糖苷;4)评价合成的pradimicin类似物的抗真菌和抗病毒活性。生物合成工程与化学合成相结合,将产生一系列“非天然”的普拉迪米星类似物,为新型抗感染药物的开发提供新的先导化合物。首席研究员和2名共同研究员分别来自生物工程、化学生物化学、生物学等3个学科。两名研究生和四名本科生将在一名技术人员的协助下进行拟议的研究。这个多部门合作项目将根据R15资助目标,为学生研究人员提供优秀的培训机会。学生们将从这个跨学科的项目中受益,与来自不同部门和不同背景的科学家一起工作。预计该项目将促进犹他州立大学生物医学研究的合作努力,参与的学生将获得抗感染药物发现的实践经验。
英文摘要
DESCRIPTION (provided by applicant): Infectious diseases caused by pathogenic microorganisms, viruses or parasites are a major threat to human health, and lead to 16.2% of the world's annual deaths. Discovery of effective therapeutics is urgently needed to fight these diseases and save lives. Pradimicin A is an antifungal and antiviral natural product from Actinomadura hibisca P157-2. Development of pradimicins into anti-infective drugs has been hampered by their poor water solubility and side effects. To take advantage of the significant biological activities of pradimicin A and find promising anti-infective drug candidates, this Academic Research Enhancement Award (AREA) R15 application is to study the biosynthetic pathway of pradimicin A and generate novel pradimicin analogs using both enzymatic and chemical methods. Three central hypotheses for the proposed research are: 1) The complete pradimicin A biosynthetic pathway can be reconstituted and engineered in a heterologous host; 2) Foreign sugar moieties and the corresponding glycosyltransferases can be engineered into the pradimicin biosynthetic pathway; and 3) New pradimicin analogs such as those with different amino sugars have antifungal and antiviral activities. The investigators will test these central hypotheses and accomplish the overall objective of this project by pursuing four specific aims: 1) Investigate the late tailoring steps in the biosynthesis of pradimicin A; 2) Engineer the biosynthesis of novel pradimicin analogs; 3) Chemically synthesize novel pradimicin glycosides; and 4) Evaluate the synthesized pradimicin analogs for antifungal and antiviral activities. With the combination of biosynthetic engineering and chemical synthesis, a series of "unnatural" pradimicin analogs will be generated, which may provide novel lead compounds for new anti- infective drug discovery. The PI and two Co-investigators are from three different departments including biological engineering, chemistry and biochemistry, and biology, respectively. Two graduate and four undergraduate students will perform the proposed research, with assistance from a technician. This multi-departmental collaborative project will provide outstanding training opportunities for student researchers, in accordance with R15 grant objectives. The students will benefit from this interdisciplinary project by working with scientists from different departments and with various backgrounds. It is expected that this project will promote collaborative efforts in biomedical research at Utah State University and the involved students will gain hands-on experience in anti- infective drug discovery. PUBLIC HEALTH RELEVANCE: This project aims to generate a library of novel pradimicin analogs using a combination of enzymatic and chemical methods, and evaluate the antifungal and antiviral activities of these synthesized compounds. The objectives of this proposal are consistent with the goals of the NIH Academic Research Enhancement Award (AREA) R15 program, and will have a significant impact on public health by providing promising molecules for new anti-infective drug discovery. This multi-departmental project will be conducted by a team of researchers consisting of three faculty members, a technician, two graduate students, and four undergraduate students.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1002/cbic.201402306
发表时间: 2014-10-13
期刊: CHEMBIOCHEM
影响因子: 3.2
作者: [Napan, Kandy, Zhang, Shuwei, Morgan, Whitney, Anderson, Thomas, Takemoto, Jon Y., Zhan, Jixun]
通讯作者: Zhan, Jixun
DOI: 10.1016/j.bmcl.2011.10.075
发表时间: 2012-01-01
期刊: BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
影响因子: 2.7
作者: [Napan, Kandy L., Zeng, Jia, Takemoto, Jon Y., Zhan, Jixun]
通讯作者: Zhan, Jixun
DOI: 10.1016/j.bmcl.2015.01.043
发表时间: 2015-03-15
期刊: BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
影响因子: 2.7
作者: [Napan, Kandy L., Zhang, Shuwei, Anderson, Thomas, Takemoto, Jon Y., Zhan, Jixun]
通讯作者: Zhan, Jixun
海外基金